An evaluation of piroxicam, a new non-steroidal anti-inflammatory agent. A multicentre trial

S Afr Med J. 1981 Jun 13;59(25):915-6.


A multicentre trial involving 1350 patients evaluated by 310 practitioners throughout South Africa was conducted to determine whether overseas studies relating to the efficacy and toleration of piroxicam (Feldene; Pfizer) would be confirmed in the local environment. Piroxicam, a member of a new class of non-steroidal anti-inflammatory agents, possesses a long plasma half-life permitting a once-a-day dosage regimen in osteo-arthrosis, rheumatoid arthritis, ankylosing spondylitis, acute musculoskeletal disorders and acute gout. In this study it was found to provide significant relief of pain and stiffness and to have a relatively low side-effect profile, confirming that it is a useful addition to current non-steroidal anti-inflammatory drug therapy.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anti-Inflammatory Agents / therapeutic use*
  • Clinical Trials as Topic
  • Female
  • Humans
  • Male
  • Middle Aged
  • Piroxicam
  • Pyridines / adverse effects
  • Pyridines / therapeutic use*
  • Rheumatic Diseases / drug therapy*
  • Thiazines / adverse effects
  • Thiazines / therapeutic use*


  • Anti-Inflammatory Agents
  • Pyridines
  • Thiazines
  • Piroxicam